6‑Month JAK‑like Efficacy: Anaptys' Rosnilimab Phase 2b Accepted for ACR Late‑Breaking Oral Presenta

Phase 2b rosnilimab data accepted for a late-breaking oral at ACR Convergence; shows JAK-like efficacy through six months and three months off-drug durability. Presentation Oct. 29; Abstract 2215555.

via: https://www.stocktitan.net/news/ANAB/anaptys-announces-late-breaking-oral-presentation-of-complete-phase-z3614q6rsfbv.html